SF-9-2

• Target :

  PD-1/PD-L1|||ERK|||JNK|||GSK-3|||Cadherin|||Bcl-2 Family|||Caspase|||p38 MAPK|||Apoptosis|||IFNAR

• Related Pathways :

  Cytoskeletal Signaling|||Cell Cycle/Checkpoint|||MAPK|||PI3K/Akt/mTOR signaling|||Immunology/Inflammation|||Proteases/Proteasome|||Apoptosis|||Stem Cells

• Bioactivity :

  SF-9-2 is a PD-L1/PD-1 binding inhibitor with an IC50 of 24.9 nM. It suppresses epithelial-mesenchymal transition, migration, invasion, and proliferation of SK-N-SH cells, while also inducing apoptosis and causing cell cycle arrest. SF-9-2 blocks PD-L1-induced growth of SK-N-SH cells via the MAPK signaling pathway. It restores GSK-3? activity and enhances PD-L1 degradation through the ubiquitin-proteasome pathway. In the SK-N-SH NOG mouse model, SF-9-2 inhibits tumor growth without notable toxicity. Additionally, SF-9-2 acts as an immune checkpoint inhibitor, blocking PD-L1 to restore T cell function and is applicable to neuroblastoma research.

• Smiles :

  N#CC1=CN=CC(=C1)COC2=CC(OCC3=CC=CC(C=4C=CC=CC4F)=C3CF)=CC=C2CNCCO

• Molecular Formula :

  C30H27F2N3O3

• Molecular Weight :

  515.55

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  3053768-78-5